{"id":2524,"date":"2024-03-15T05:12:03","date_gmt":"2024-03-15T05:12:03","guid":{"rendered":"https:\/\/curateqbio.com\/?p=2524"},"modified":"2024-03-16T05:35:13","modified_gmt":"2024-03-16T05:35:13","slug":"curateq-biologics-successfully-completes-phase-1-trial-for-omalizumab-biosimilar","status":"publish","type":"post","link":"https:\/\/curateqbio.com\/curateq-biologics-successfully-completes-phase-1-trial-for-omalizumab-biosimilar\/","title":{"rendered":"CuraTeQ Biologics successfully completes Phase 1 trial for Omalizumab biosimilar"},"content":{"rendered":"\r\n<section id=\"post-content-block_64ccb899d4420\" class=\"post-content\">\r\n    <div class=\"text-container\">\r\n        <h3 class=\"article_desc\">CuraTeQ Biologics Private Limited, a wholly owned subsidiary of Aurobindo Pharma Ltd, announced that their Omalizumab biosimilar candidate BP11 has met the Phase 1 trial end points vis-\u00e0-vis the EU and US sourced reference product Xolair. The PK\/PD trial was conducted in 165 healthy volunteers in Australia and New Zealand.<\/h3>\n<p>\u201cThe primary objective was to prove pharmacokinetic (PK) equivalence between BP11, US and EU sourced Xolair. 165 healthy volunteers were randomized to receive either BP11 or EU or US licensed Omalizumab via subcutaneous route of administration. Results of both primary parameters, i.e. maximum serum concentration (Cmax) and area under concentration-time curve from time zero to infinity (AUC0-inf), were contained within 80-125% bioequivalence limit demonstrating PK equivalence between BP11 and both US and EU sourced Xolair. BP11 also had similar IgE levels to Xolair demonstrating comparable pharmacodynamic profile versus US and EU sourced Xolair. The safety and immunogenicity profiles were also found comparable versus the originator\u2019s product,\u201d said Dr. Arpit Prajapati, Head of Clinical Sciences at CuraTeQ Biologics.<\/p>\n<p>Dr. Disha Dadke, Associate President and Head R&amp;D, said, \u201cWe have initiated a Phase 3 study of our Omalizumab candidate BP11 for the treatment of chronic spontaneous or idiopathic urticaria, which is a presence of hives that are itchy and can last for a number of weeks with no apparent external trigger. The Phase 3 efficacy and safety study is being conducted across multiple sites in seven European countries and in 600 patients with chronic spontaneous urticaria. Additionally, a separate Phase 3 trial in asthma patients is being carried out in the Indian population. CuraTeQ intends to file the Omalizumab biosimilar product in India in 2024 and is on track to file the product in regulated markets in 2025.\u201d<\/p>\n<p><strong>About CuraTeQ:<\/strong> CuraTeQ Biologics (a wholly owned subsidiary of Aurobindo Pharma Ltd.) is a biopharmaceutical company based out of Hyderabad, India. Our vision is to improve the wellbeing of patients suffering from debilitating illnesses by providing them access to high quality and cost-effective biosimilars. CuraTeQ has a development pipeline of 14 biosimilars, of which, three products have been filed with EMA, one product has been filed with MHRA, and four more products are in global phase 3 clinical trials.<\/p>\n<p>For more information, write to us at info@curateqbio.com<\/p>\n    <\/div>\r\n<\/section>\r\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":2379,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[7],"tags":[42,43,44,12,19,22,41],"class_list":["post-2524","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-release","tag-phase-1-study","tag-xolair","tag-omalizumab","tag-curateq-biologics","tag-aurobindo-pharma","tag-biosimilar-development","tag-omalizumab-biosimilar"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>CuraTeQ Biologics successfully completes Phase 1 trial for Omalizumab biosimilar - CuraTeQ Biologics<\/title>\n<meta name=\"description\" content=\"CuraTeQ Biologics announces the successful Phase 1 clinical study outcome of their BP11 product (a biosimilar to Xolair).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/curateqbio.com\/curateq-biologics-successfully-completes-phase-1-trial-for-omalizumab-biosimilar\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CuraTeQ Biologics successfully completes Phase 1 trial for Omalizumab biosimilar - CuraTeQ Biologics\" \/>\n<meta property=\"og:description\" content=\"CuraTeQ Biologics announces the successful Phase 1 clinical study outcome of their BP11 product (a biosimilar to Xolair).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/curateqbio.com\/curateq-biologics-successfully-completes-phase-1-trial-for-omalizumab-biosimilar\/\" \/>\n<meta property=\"og:site_name\" content=\"CuraTeQ Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-15T05:12:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-16T05:35:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/curateqbio.com\/wp-content\/uploads\/2022\/01\/3966736-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"curateq-admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"curateq-admin\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/curateqbio.com\/curateq-biologics-successfully-completes-phase-1-trial-for-omalizumab-biosimilar\/\",\"url\":\"https:\/\/curateqbio.com\/curateq-biologics-successfully-completes-phase-1-trial-for-omalizumab-biosimilar\/\",\"name\":\"CuraTeQ Biologics successfully completes Phase 1 trial for Omalizumab biosimilar - CuraTeQ Biologics\",\"isPartOf\":{\"@id\":\"https:\/\/curateqbio.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/curateqbio.com\/curateq-biologics-successfully-completes-phase-1-trial-for-omalizumab-biosimilar\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/curateqbio.com\/curateq-biologics-successfully-completes-phase-1-trial-for-omalizumab-biosimilar\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/curateqbio.com\/wp-content\/uploads\/2022\/01\/3966736-scaled.jpg\",\"datePublished\":\"2024-03-15T05:12:03+00:00\",\"dateModified\":\"2024-03-16T05:35:13+00:00\",\"author\":{\"@id\":\"https:\/\/curateqbio.com\/#\/schema\/person\/ada896a037198d1a34fed5ca62571235\"},\"description\":\"CuraTeQ Biologics announces the successful Phase 1 clinical study outcome of their BP11 product (a biosimilar to Xolair).\",\"breadcrumb\":{\"@id\":\"https:\/\/curateqbio.com\/curateq-biologics-successfully-completes-phase-1-trial-for-omalizumab-biosimilar\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/curateqbio.com\/curateq-biologics-successfully-completes-phase-1-trial-for-omalizumab-biosimilar\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/curateqbio.com\/curateq-biologics-successfully-completes-phase-1-trial-for-omalizumab-biosimilar\/#primaryimage\",\"url\":\"https:\/\/curateqbio.com\/wp-content\/uploads\/2022\/01\/3966736-scaled.jpg\",\"contentUrl\":\"https:\/\/curateqbio.com\/wp-content\/uploads\/2022\/01\/3966736-scaled.jpg\",\"width\":2560,\"height\":1707,\"caption\":\"CuraTeQ Biologics successfully completes Phase 1 trial for Omalizumab biosimilar.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/curateqbio.com\/curateq-biologics-successfully-completes-phase-1-trial-for-omalizumab-biosimilar\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/curateqbio.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CuraTeQ Biologics successfully completes Phase 1 trial for Omalizumab biosimilar\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/curateqbio.com\/#website\",\"url\":\"https:\/\/curateqbio.com\/\",\"name\":\"CuraTeQ Biologics\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/curateqbio.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/curateqbio.com\/#\/schema\/person\/ada896a037198d1a34fed5ca62571235\",\"name\":\"curateq-admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/curateqbio.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1f5bfa143bdcee393defa3cc5e4dd1b8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1f5bfa143bdcee393defa3cc5e4dd1b8?s=96&d=mm&r=g\",\"caption\":\"curateq-admin\"},\"sameAs\":[\"http:\/\/curateq.local\"],\"url\":\"https:\/\/curateqbio.com\/author\/curateq-admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CuraTeQ Biologics successfully completes Phase 1 trial for Omalizumab biosimilar - CuraTeQ Biologics","description":"CuraTeQ Biologics announces the successful Phase 1 clinical study outcome of their BP11 product (a biosimilar to Xolair).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/curateqbio.com\/curateq-biologics-successfully-completes-phase-1-trial-for-omalizumab-biosimilar\/","og_locale":"en_US","og_type":"article","og_title":"CuraTeQ Biologics successfully completes Phase 1 trial for Omalizumab biosimilar - CuraTeQ Biologics","og_description":"CuraTeQ Biologics announces the successful Phase 1 clinical study outcome of their BP11 product (a biosimilar to Xolair).","og_url":"https:\/\/curateqbio.com\/curateq-biologics-successfully-completes-phase-1-trial-for-omalizumab-biosimilar\/","og_site_name":"CuraTeQ Biologics","article_published_time":"2024-03-15T05:12:03+00:00","article_modified_time":"2024-03-16T05:35:13+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/curateqbio.com\/wp-content\/uploads\/2022\/01\/3966736-scaled.jpg","type":"image\/jpeg"}],"author":"curateq-admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"curateq-admin"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/curateqbio.com\/curateq-biologics-successfully-completes-phase-1-trial-for-omalizumab-biosimilar\/","url":"https:\/\/curateqbio.com\/curateq-biologics-successfully-completes-phase-1-trial-for-omalizumab-biosimilar\/","name":"CuraTeQ Biologics successfully completes Phase 1 trial for Omalizumab biosimilar - CuraTeQ Biologics","isPartOf":{"@id":"https:\/\/curateqbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/curateqbio.com\/curateq-biologics-successfully-completes-phase-1-trial-for-omalizumab-biosimilar\/#primaryimage"},"image":{"@id":"https:\/\/curateqbio.com\/curateq-biologics-successfully-completes-phase-1-trial-for-omalizumab-biosimilar\/#primaryimage"},"thumbnailUrl":"https:\/\/curateqbio.com\/wp-content\/uploads\/2022\/01\/3966736-scaled.jpg","datePublished":"2024-03-15T05:12:03+00:00","dateModified":"2024-03-16T05:35:13+00:00","author":{"@id":"https:\/\/curateqbio.com\/#\/schema\/person\/ada896a037198d1a34fed5ca62571235"},"description":"CuraTeQ Biologics announces the successful Phase 1 clinical study outcome of their BP11 product (a biosimilar to Xolair).","breadcrumb":{"@id":"https:\/\/curateqbio.com\/curateq-biologics-successfully-completes-phase-1-trial-for-omalizumab-biosimilar\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/curateqbio.com\/curateq-biologics-successfully-completes-phase-1-trial-for-omalizumab-biosimilar\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/curateqbio.com\/curateq-biologics-successfully-completes-phase-1-trial-for-omalizumab-biosimilar\/#primaryimage","url":"https:\/\/curateqbio.com\/wp-content\/uploads\/2022\/01\/3966736-scaled.jpg","contentUrl":"https:\/\/curateqbio.com\/wp-content\/uploads\/2022\/01\/3966736-scaled.jpg","width":2560,"height":1707,"caption":"CuraTeQ Biologics successfully completes Phase 1 trial for Omalizumab biosimilar."},{"@type":"BreadcrumbList","@id":"https:\/\/curateqbio.com\/curateq-biologics-successfully-completes-phase-1-trial-for-omalizumab-biosimilar\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/curateqbio.com\/"},{"@type":"ListItem","position":2,"name":"CuraTeQ Biologics successfully completes Phase 1 trial for Omalizumab biosimilar"}]},{"@type":"WebSite","@id":"https:\/\/curateqbio.com\/#website","url":"https:\/\/curateqbio.com\/","name":"CuraTeQ Biologics","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/curateqbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/curateqbio.com\/#\/schema\/person\/ada896a037198d1a34fed5ca62571235","name":"curateq-admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/curateqbio.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1f5bfa143bdcee393defa3cc5e4dd1b8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1f5bfa143bdcee393defa3cc5e4dd1b8?s=96&d=mm&r=g","caption":"curateq-admin"},"sameAs":["http:\/\/curateq.local"],"url":"https:\/\/curateqbio.com\/author\/curateq-admin\/"}]}},"_links":{"self":[{"href":"https:\/\/curateqbio.com\/wp-json\/wp\/v2\/posts\/2524","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/curateqbio.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/curateqbio.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/curateqbio.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/curateqbio.com\/wp-json\/wp\/v2\/comments?post=2524"}],"version-history":[{"count":4,"href":"https:\/\/curateqbio.com\/wp-json\/wp\/v2\/posts\/2524\/revisions"}],"predecessor-version":[{"id":2529,"href":"https:\/\/curateqbio.com\/wp-json\/wp\/v2\/posts\/2524\/revisions\/2529"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/curateqbio.com\/wp-json\/wp\/v2\/media\/2379"}],"wp:attachment":[{"href":"https:\/\/curateqbio.com\/wp-json\/wp\/v2\/media?parent=2524"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/curateqbio.com\/wp-json\/wp\/v2\/categories?post=2524"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/curateqbio.com\/wp-json\/wp\/v2\/tags?post=2524"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}